Evidence map›Paper›PMID 38170586›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials.

Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, Dongsheng Tu, Stephanie Y Brule, Rachel Goodwin, Derek J Jonker, Timothy Price, John R Zalcberg, Malcolm J Moore and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

Joao Paulo Solar VasconcelosBC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-7870-7765
Nan ChenDepartment of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.ORCID 0009-0002-7197-8164
Emma TitmussBC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-1993-6912
Dongsheng TuCanadian Cancer Trials Group, Kingston, Ontario, Canada.ORCID 0000-0003-4842-2184
Stephanie Y BruleThe Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-8572-9997
Rachel GoodwinThe Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0000-0002-0250-8479
Derek J JonkerThe Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.ORCID 0009-0008-1103-3429
Timothy PriceQueen Elizabeth Hospital, Adelaide, South Australia, Australia.ORCID 0000-0002-3922-2693
John R ZalcbergDepartment of Medical Oncology, Alfred Health and School of Public Health, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0002-6624-0782
Malcolm J MoorePrincess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.ORCID 0009-0007-7493-3558
Christos S KarapetisFlinders University, Adelaide, South Australia, Australia.ORCID 0000-0003-1741-996X
Lillian SiuPrincess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-3500-0540
Jeremy ShapiroDepartment of Medical Oncology, Alfred Health and School of Public Health, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.ORCID 0009-0007-9290-8145
John SimesThe University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-3740-7563
Sharlene GillBC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-3306-3617
Chris J O'CallaghanCanadian Cancer Trials Group, Kingston, Ontario, Canada.ORCID 0000-0003-2896-666X
Jonathan M LoreeBC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-8189-2132
University of British Columbia Hospital · CAOttawa Hospital · CAAlfred Health · AUCanadian Cancer Society · CAPrincess Margaret Cancer Centre · CAFlinders University · AUQueen Elizabeth Hospital · AUQueen's University · CAThe University of Sydney · AU

Funding

Bristol-Myers Squibb (BMS)Canadian Cancer Society (CCS)Michael Smith Health Research BC (MSFHR)
6 · The paper itself

Abstract

purposeSidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). Transverse colon has been historically excluded from several analyses of sidedness and the optimal division between left- and right-sided colorectal cancer is unclear. We investigated transverse colon primary tumor location as a biomarker in mCRC. EXPERIMENTAL

designPooled analysis of CCTG/AGITG CO.17 and CO.20 trials of cetuximab in chemotherapy-refractory mCRC. Outcomes of patients with RAS/BRAF wild-type (WT) mCRC from CO.17 and KRAS WT mCRC from CO.20 were analyzed according to location.

resultsA total of 553 patients were analyzed, 32 (5.8%) with cancers from the transverse, 101 (18.3%) from right, and 420 from (75.9%) left colon. Transverse mCRC failed to reach significant benefit from cetuximab versus best supportive care (BSC) for overall survival [OS; median, 5.9 vs. 2.1 months; HR, 0.63; 95% confidence interval (CI), 0.28-1.42; P=0.26] and progression-free survival (PFS; median, 1.8 vs. 1.3 months; HR, 0.57; 95% CI, 0.26-1.28; P=0.16). Analyzing exclusively patients randomized to cetuximab, right-sided and transverse had comparable outcomes for OS (median, 5.6 vs. 5.9 months; HR, 0.82; 95% CI, 0.50-1.34; P=0.43) and PFS (median, 1.9 vs. 1.8 months; HR, 0.78; 95% CI, 0.49-1.26; P=0.31). Patients with left-sided mCRC had superior outcomes with cetuximab compared with transverse for OS (median, 9.7 vs. 5.9 months; HR, 0.42; 95% CI, 0.27-0.67; P=0.0002) and PFS (median, 3.8 vs. 1.8 months; HR, 0,49; 95% CI, 0.31-0.76; P=0.001). Location was not prognostic in patients treated with BSC alone.

conclusionsTransverse mCRC has comparable prognostic and predictive features with right-sided mCRC.

Indexed as

Colonic NeoplasmsColon, TransverseColorectal NeoplasmsRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBiomarkersCetuximabHumansRandomized Controlled Trials as TopicBiomarkersCetuximab

Identifiers

PMID38170586
PMCPMC10940852
OpenAlexW4390535948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.